Basic Information of Orforglipron
- Product Name: Orforglipron
- CAS No.: 2212020-52-3
- Molecular Formula: C₄₈H₄₈F₂N₁₀O₅
- Molecular Weight: 882.96
- Category: Anti-diabetic Active Pharmaceutical Ingredient
- Indications: Obesity/Overweight, Type 2 Diabetes
- Dosage form: Tablet (once daily, no food/water restrictions)
What is Orforglipron？
Orforglipron (CAS: 2212020-52-3) is a novel oral non-peptide GLP-1 receptor agonist API.It is a small molecule compound that appears as a white to off-white powder.Oflogliron, a finished drug product pioneered by Lilai Company, has successfully launched in the United States (marketed under the trade name Foundayo) and is currently undergoing the marketing application process in China.
This preparation is primarily indicated for the chronic weight management of obese or overweight adults, and may also be used in treatment-related studies for Type 2 diabetes.
For more information about Foundayo, please visit www.foundayo.lilly.com.
Why choose Highassay?
Highassay is a professional Orforglipron API (CAS 2212020-52-3) supplier based in China. We provide Orforglipron powder (purity≥99%) for you.Choose our Orforglipron to safeguard your scientific research journey.
- Strict Quality Control
Our manufacturing facility complies with GMP production standards and is equipped with HPLC/LC-MS analytical instrumentation and in-house testing capabilities. Furthermore, we provide accompanying documentation—including Batch COAs, MSDSs, and product specifications—with every shipment.
- Flexible Packaging Specifications
We offer standard packaging options ranging from 1g, 5g, 10g, and 100g up to 1kg. We also support custom packaging services, catering to requirements across small-scale trials, pilot studies, and large-scale R&D.
- Professional Storage and Transportation Solutions
Our products are stored in sealed, light-protected conditions at 2–8°C (for short-term storage) or at -20°C (for long-term storage). These rigorous storage and transport conditions serve to maximize the preservation of both the product’s physical integrity and the activity of its raw materials.
- Efficient & Responsive Supply
Rapid delivery of small batches (supporting laboratory R&D); stable supply of large- batch(supporting clinical-stage requirements).
Buy Orforglipron api for research use from Highassay.If you are interested in Orforglipron price per gram,contect us now.
Physicochemical Properties of Orforglipron
- Appearance: White to off-white powder
- Purity: ≥99%(HPLC)
- Salt Form: Free base / Hemicalcium salt
- Total Impurities: <1.0%
- Single Impurity: <0.2%
- Analytical Method: Liquid Chromatography (LC-MS)
- Storage Conditions: Store sealed and protected from light at 2–8°C (short-term); -20°C (long-term)
- Applications: Pharmaceutical R&D, generic drug development, scientific research, export of legal pharmaceutical raw materials
- Not for Use In: Food, dietary supplements, animal feed, cosmetics, or direct personal use
- Orforglipron patent status:During the patent protection period
Mechanism of Action of Orforglipron
As a small-molecule non-peptide compound, it specifically binds to and activates GLP‑1R, increases insulin secretion in a glucose-dependent pattern, reduces glucagon secretion, delays gastric emptying.It enhances the feeling of fullness through central nervous system action, resulting in simultaneous blood glucose lowering and body weight management.
Who we serve
Note: Due to patent protection restrictions, the olflugelli active pharmaceutical ingredient we provide is limited to laboratory research, pharmacological experiments, analytical method development, and early-stage generic drug development.Not applicable for human clinical trials, commercial pharmaceutical manufacturing, or use in health supplements/food additives.
If you intend to use the Orfogliron API for legitimate research purposes—such as new drug discovery, generic drug development,Orfogliron reference standard, impurity studies, or the establishment of analytical testing methods—you may proceed with your purchase as usual.
Orforglipron VS Semaglutide
Orforglipron and semaglutide both belong to the same broad class of medications: GLP-1 receptor agonists.
Semaglutide is a peptide and comes in an injectable form; its oral absorption is poor.
Omphiglione is a non-peptide small molecule, taken as an oral tablet.The structure is more stable, and bioavailability is higher.
Orforglipron vs Tirzepatide
- Orforglipron vs Tirzepatide
| Item | Orforglipron (Foundayo) | Tirzepatide (Zepbound) |
| Product Name | Orforglipron | Tirzepatide |
| Administration | Once-daily oral tablet | Once-weekly subcutaneous injection |
| Mechanism of Action | Single-target GLP1 receptor agonist | Dual-target GIP/GLP1 receptor agonist |
| Indications | Weight management in adults with obesity or overweight | Weight management, obstructive sleep apnea |
| Weight Reduction at 72 Weeks | 7.5%–11.2% | 15%–22% |
| Glycemic Control (A1C Reduction) | 1.24%–1.6% | 1.87%–2.59% |
| Bioavailability | 20%–40% (limited oral absorption) | Approx. 80% (excellent absorption via injection) |
Formulation: Tablet (taken once daily, independent of food intake)
Formulation Advantages: As a once-daily oral medication,it is more convenient than the injectable form.
Orforglipron is a prescription medication that must be taken and adjusted under the guidance of a physician.
Orforglipron tablets are available in several strengths: 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg.
The initial dose is 0.8 mg once daily.Increase in a stepwise manner every 30 days, based on tolerance.Do not arbitrarily skip doses or increase the dosage ahead of schedule.
Both can be used for weight loss, but there are significant differences in the route of administration, mechanism of action, efficacy, and cost (refer to the table above).
The two medications should not be used concurrently; however, Orforglipron may serve as an oral maintenance option following a transition from Zepbound treatment.
Products you are interested in
Specifications of Orforglipron
| Item | Specification | Remarks |
| Product Name | Orforglipron | For research & development use only |
| Appearance | White to off-white crystalline or amorphous powder, odorless | Visual inspection |
| Purity (HPLC) | ≥99% | Key specification |
| Maximum single impurity | ≤0.15% | Tested by HPLC |
| Total impurities | ≤0.5% | Tested by HPLC |
| Loss on drying | ≤0.5% | Dry to constant weight at 105°C |
| Residue on ignition | ≤0.1% | Complies with pharmacopoeia standards |
| Residual solvents | Complies with ICH Q3C, limits for methanol, ethanol, etc. are satisfied | Tested by GC |
| Heavy metals | ≤10 ppm | Complies with ICH Q3D limits |
| Microbial limits | TAMC ≤100 cfu/g; TYMC ≤10 cfu g; absence of Escherichia coli and Salmonella | Microbial examination |
| Packaging | 1g/5g/10g (aluminum foil bag); 100g/500g/1kg (fluorinated bottle) | Customizable upon request |
| Storage | Sealed, dry, protected from light, stored at 2–8°C | Avoid moisture and high temperature |
| Shelf life | 2 years | Under recommended storage conditions |
| Intended use | For laboratory research, pharmaceutical R&D, analytical testing, and generic drug pre-development only | For compliant research use |
| Restrictions of use | Not for human clinical use, commercial formulation production, food, health product or feed additives | Strictly observed |
